Free Trial

Akari Therapeutics (AKTX) SEC Filings & 10K Form

Akari Therapeutics logo
$1.38 -0.02 (-1.43%)
Closing price 05/2/2025 03:59 PM Eastern
Extended Trading
$1.35 -0.03 (-2.17%)
As of 05/2/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recent Akari Therapeutics SEC Filings

DateFilerForm TypeView
04/29/2025
4:00 PM
Akari Therapeutics (Issuer)
Patel Sandip I (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/16/2025
7:00 AM
Akari Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/15/2025
3:33 PM
Akari Therapeutics (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/24/2025
4:00 PM
Akari Therapeutics (Issuer)
Gaslightwala Abizer (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/24/2025
4:00 PM
Akari Therapeutics (Issuer)
Huh Hoyoung (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/24/2025
4:00 PM
Akari Therapeutics (Issuer)
Hombeck Torsten (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/24/2025
4:00 PM
Akari Therapeutics (Issuer)
Prudo-Chlebosz Raymond (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/24/2025
4:00 PM
Akari Therapeutics (Issuer)
Patel Sandip I (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/24/2025
4:00 PM
Akari Therapeutics (Issuer)
Patel Samir Rashmikant (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/24/2025
4:00 PM
Akari Therapeutics (Issuer)
Bazemore Robert B (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/24/2025
4:00 PM
Akari Therapeutics (Issuer)
Neal James R (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/20/2025
7:50 AM
Akari Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/10/2025
4:00 PM
Akari Therapeutics (Issuer)
Gaslightwala Abizer (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/10/2025
4:00 PM
Akari Therapeutics (Issuer)
Bazemore Robert B (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/10/2025
4:00 PM
Akari Therapeutics (Issuer)
Neal James R (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/10/2025
4:00 PM
Akari Therapeutics (Issuer)
Patel Samir Rashmikant (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/10/2025
4:00 PM
Akari Therapeutics (Issuer)
Prudo-Chlebosz Raymond (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/10/2025
4:00 PM
Akari Therapeutics (Issuer)
Huh Hoyoung (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2025
8:10 AM
Akari Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/07/2025
3:30 PM
Akari Therapeutics (Issuer)
Gaslightwala Abizer (Reporting)
Form 4/A
01/13/2025
7:00 AM
Akari Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/13/2025
7:05 AM
Akari Therapeutics (Issuer)
Hombeck Torsten (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/13/2025
7:05 AM
Akari Therapeutics (Issuer)
Gaslightwala Abizer (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/10/2025
4:30 PM
Akari Therapeutics (Issuer)
Neal James R (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/07/2025
3:30 PM
Akari Therapeutics (Issuer)
Patel Samir Rashmikant (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/30/2024
3:30 PM
Akari Therapeutics (Issuer)
Gaslightwala Abizer (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/30/2024
3:30 PM
Akari Therapeutics (Issuer)
Patel Samir Rashmikant (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/27/2024
3:30 PM
Akari Therapeutics (Issuer)
Patel Samir Rashmikant (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/27/2024
3:30 PM
Akari Therapeutics (Issuer)
Gaslightwala Abizer (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/26/2024
3:30 PM
Akari Therapeutics (Issuer)
Patel Samir Rashmikant (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/26/2024
3:30 PM
Akari Therapeutics (Issuer)
Patel Samir Rashmikant (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/26/2024
3:30 PM
Akari Therapeutics (Issuer)
Gaslightwala Abizer (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
12/26/2024
3:30 PM
Akari Therapeutics (Issuer)
Neal James R (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/20/2024
3:30 PM
Akari Therapeutics (Issuer)
Hombeck Torsten (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
12/18/2024
3:30 PM
Akari Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/12/2024
3:30 PM
Akari Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/06/2024
3:00 PM
Akari Therapeutics (Subject)
Patel Samir Rashmikant (Filed by)
Form SC 13D/A
12/03/2024
4:48 PM
Akari Therapeutics (Issuer)
Prudo-Chlebosz Raymond (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/03/2024
4:50 PM
Akari Therapeutics (Issuer)
Patel Samir Rashmikant (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/22/2024
3:30 PM
Akari Therapeutics (Issuer)
Huh Hoyoung (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
11/22/2024
3:30 PM
Akari Therapeutics (Issuer)
Neal James R (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
Silicon Valley Gold Rush (Ad)

A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.

Gates and Altman are betting big—see why
11/22/2024
3:30 PM
Akari Therapeutics (Issuer)
Patel Sandip I (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
11/19/2024
3:48 PM
Akari Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/18/2024
7:02 PM
Akari Therapeutics (Issuer)
Patel Samir Rashmikant (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/14/2024
3:27 PM
Akari Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/08/2024
7:00 AM
Akari Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/01/2024
5:00 PM
Akari Therapeutics (Issuer)
Patel Samir Rashmikant (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/15/2024
7:51 AM
Akari Therapeutics (Subject)
Form 425
10/14/2024
11:15 PM
Akari Therapeutics (Filer)
Form EFFECT
10/11/2024
3:52 PM
Akari Therapeutics (Filer)
Form 424B3
10/09/2024
3:27 PM
Akari Therapeutics (Filer)
Form S-4/A
10/04/2024
3:30 PM
Akari Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/02/2024
5:34 PM
Akari Therapeutics (Issuer)
Patel Samir Rashmikant (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/30/2024
5:43 AM
Akari Therapeutics (Filer)
Form S-4/A
09/18/2024
3:34 PM
Akari Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/18/2024
3:36 PM
Akari Therapeutics (Issuer)
Bazemore Robert B (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
09/18/2024
3:40 PM
Akari Therapeutics (Issuer)
Bazemore Robert B (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/15/2024
11:15 PM
Akari Therapeutics (Filer)
Form EFFECT
09/13/2024
4:30 PM
Akari Therapeutics (Filer)
Form S-4
Registration statement under Securities Act of 1933  
09/06/2024
4:23 PM
Akari Therapeutics (Filer)
Form S-3
Registration statement under Securities Act of 1933  
09/06/2024
4:07 PM
Akari Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/23/2024
3:30 PM
Akari Therapeutics (Filer)
Form 8-K/A
08/19/2024
3:30 PM
Akari Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/19/2024
3:15 PM
Akari Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/15/2024
3:15 PM
Akari Therapeutics (Filer)
Form NT 10-Q
07/02/2024
3:30 PM
Akari Therapeutics (Issuer)
Akari Therapeutics (Issuer)
Prudo-Chlebosz Raymond (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/02/2024
3:30 PM
Akari Therapeutics (Issuer)
WILLIAMS DONALD A (Reporting)
WILLIAMS DONALD A (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/02/2024
3:30 PM
Akari Therapeutics (Issuer)
Hashad Mohamed Wa'el Ahmed (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/02/2024
3:30 PM
Akari Therapeutics (Issuer)
Patel Samir Rashmikant (Reporting)
Patel Samir Rashmikant (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/02/2024
3:30 PM
Akari Therapeutics (Issuer)
Akari Therapeutics (Issuer)
Grissinger Michael (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/20/2024
6:30 AM
Akari Therapeutics (Subject)
RPC Pharma Ltd (Filed by)
Form SC 13D/A
06/07/2024
5:00 PM
Akari Therapeutics (Subject)
Patel Samir Rashmikant (Filed by)
Form SC 13D
06/04/2024
3:45 PM
Akari Therapeutics (Issuer)
Prudo-Chlebosz Raymond (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/04/2024
3:45 PM
Akari Therapeutics (Issuer)
Patel Samir Rashmikant (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/04/2024
3:30 PM
Akari Therapeutics (Subject)
Form 425
06/04/2024
7:02 AM
Akari Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/16/2024
7:05 AM
Akari Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/15/2024
3:47 PM
Akari Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:AKTX) was last updated on 5/5/2025 by MarketBeat.com Staff
From Our Partners